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Abstract  
Posttraumatic stress disorder (PTSD) is a serious and global problem, a psychiatric disorder 
that frequently occurs with different comorbidities, and is associated with a high suicide rate. 
Pathophysiologically, both PTSD and suicidal behavior are related to disturbances in the 
central serotonergic system. Serotonin (5-hydroxytryptamine, 5-HT) controls emotional 
behavior, anxiety, impulsivity and aggression, and nearly all known antidepressants and 
antianxiety drugs affect 5-HT transmission. Platelet 5-HT can be used as a limited peripheral 
marker of the central serotonergic synaptosomes, since it is related to particular basic 
psychopathological characteristics of several psychiatric disorders. Platelet 5-HT concentration 
has been reported to be similar in PTSD subjects and healthy controls, but suicidal patients 
across different psychiatric diagnoses have reduced platelet 5-HT concentration. This study 
examined platelet 5-HT concentration by the spectrofluorimetric method in male subjects: 73 
suicidal and 47 non-suicidal veterans with current and chronic combat related PTSD, 45 
suicidal and 30 non-suicidal comparative non-PTSD subjects and 147 healthy men. The 
presence of suicidal behavior (score=0, non-suicidal; scores ≥ 1, suicidal) was assessed with 
the Hamilton Depression Rating Scale-17 (HDRS). Platelet 5-HT concentration was 
significantly lower in suicidal PTSD and non-PTSD patients compared to non-suicidal 
patients or healthy controls. Since the majority of patients scored very low on item 3 of 
HDRS, no significant correlation between suicidal scores and platelet 5-HT concentration was 
found. These results show that reduced platelet 5-HT concentration is related to suicidal 
behavior in PTSD, and suggest that platelet 5-HT concentration might be used as a peripheral 
marker to predict suicidal behavior across psychiatric diagnoses.  
 
Keywords: biological marker; male subjects; platelet serotonin; combat related posttraumatic 
stress disorder; suicidal behavior  
 
Abbreviations: ANOVA, analysis of variance; CAPS, Clinician Administered PTSD Scale; 
HAMA, Hamilton Rating Scale for Anxiety; HDRS, Hamilton's Rating Scale for Depression 
17-item; HVA, homovanillic acid; 5-HIAA, 5-hydroxylindoleacetic acid; 5-HT, 5-
hydroxytryptamine, serotonin; MAO, monoamine oxidase; PANSS, Positive and Negative 
Syndrome Scale; PRP Platelet rich plasma; PTSD, posttraumatic stress disorder; SSRI, 
selective serotonin reuptake inhibitors; SCID, Structured Clinical Interview.  
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Introduction 
Posttraumatic stress disorder (PTSD) is a serious and global problem, a psychiatric disorder 
that frequently occurs with different comorbidities, and is associated with a high suicide rate 
(Kessler et al., 1999; Kozaric-Kovacic and Kocijan-Hercigonja 2001). The neurobiology of 
PTSD includes alterations in neuroendocrine and neurotransmitter systems and morphological 
changes such as reduced hippocampal volume (Ballenger et al., 2004; Van Praag, 2004; 
Nemeroff et al., 2006). The most frequent finding is altered function of the hypothalamic-
pituitary-adrenal axis, with hypersecretion of corticotrophin-releasing factor, with 
paradoxically low to normal cortisol levels, and a super-suppression of cortisol secretion after 
a low-dose of dexamethasone in a dexamethasone suppression test. The disrupted 
neurotransmitter systems in PTSD are norepinephrine, serotonin (5-hydroxytryptamine, 5-
HT), glutamate, γ-aminobutyric acid, and endogenous opioids. Combat related PTSD is 
accompanied with a high risk of suicide, and military experience, guilt about combat actions, 
survivor guilt, depression, anxiety and severe PTSD are significantly associated with suicide 
attempts (Freeman et al., 2000; Ferrada-Noli et al., 1998; Price et al., 2004). 
 
Suicidal behavior is a major social and public health problem which significantly increases 
the death toll worldwide. The complex genetic, neurobiological, and psychosocial origins of 
suicidal behavior are still unclear, but abnormalities in the serotonergic system have been 
found in suicide victims (Creminter et al., 1994; Mann, 2002; Mann, 2003). These findings 
are in line with the impairments of the central 5-HT neurotransmission found in a variety of 
behavioral and physiological abnormalities, psychiatric disorders, and in extreme violence, 
hostility, impulsivity and aggression (Lucki, 1998; Stahl, 1998). Suicide risk has been 
associated with alterations in serotonergic correlates such as lower 5-hydroxylindoleacetic 
acid (5-HIAA) and homovanillic acid (HVA) levels in patients with a history of suicide 
attempts (Jones et al., 1990; Nordstron et al., 1994), lower 3H-imipramine binding and 5-HT 
uptake in platelets of suicide attempters, and lower central 5-HT function (Roy and Linnoila 
1988; Mann 1998).  
 
Blood platelets can be used as limited peripheral model for central 5-HT neuron function 
(Stahl, 1985; Andres et al., 1993; Hrdina, 1994; Camacho and Dimsdale, 2000; Mendelson, 
2000; Goveas et al., 2004), since platelets share some similarities with the central 5-HT 
synaptosomes. The similarities lay in the pharmacodynamics of 5-HT, including uptake, 
storage and release of 5-HT, platelet monoamine oxidase (MAO) type B, 5-HT transporters 
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(Lesch et al., 1994), 5-HT2 receptors (Andres et al., 1993), α2-adrenergic receptors, and 
binding sites for 3H-imipramine, 3H-paroxetine, and 3H-LSD, and signaling mechanism which 
share identical pharmacologic and kinetic characteristics with the central nervous receptors 
and binding sites. The differences between blood platelets and 5-HT neurons are in their 
function, since platelets lack a nucleus, and they do not synthesize 5-HT (Hrdina, 1994). 
Peripheral serotonergic markers, such as platelet 5-HT, have been associated with particular 
basic psychopathological characteristics, i.e. trait markers (Askenazy et al., 2000; Mueller-
Oerlinghausen et al., 2004). Although the significance of platelet 5-HT as a marker of 
suicidality has been recently questioned (Mueller-Oerlinghausen et al., 2004), lower platelet 
5-HT has been associated with suicidal behavior in psychotic and non-psychotic depressed 
patients (Muck-Seler et al., 1996; Pivac et al., 1997), and in patients with first episode of 
psychosis (Marcinko et al., 2007). 
 
To our knowledge, there are no studies that have examined the association of platelet 5-HT 
with suicidal behavior in veterans with combat related PTSD. Hence, based on our previous 
data (Muck-Seler et al., 1996; Pivac et al., 1997; Marcinko et al., 2007), the hypothesis of this 
study was that platelet 5-HT concentration would be reduced in suicidal patients compared to 
non-suicidal PTSD patients. The aim of the study was to determine the differences in platelet 
5-HT concentration among male suicidal and non-suicidal veterans with combat related 
PTSD, male psychiatric controls with diagnoses other than PTSD (non-PTSD patients), and 
healthy men, and to determine whether platelet 5-HT concentration might be used as a 
peripheral platelet marker to predict the risk of suicidal behavior.  
 
2. Methods 
2.1. Subjects and clinical evaluation 
 
The study included male medication-free participants. The patients (120 male war 
veterans with combat related PTSD), had current and chronic PTSD, diagnosed using the 
Structured Clinical Interview for DSM-IV (SCID, First et al., 2000) based on DSM-IV 
Disorders (APA, 1994), the Clinician Administered PTSD Scale (CAPS, Weathers et al., 
2001), the Hamilton Rating Scale for Depression-17 (HDRS, Hamilton, 1960) and Anxiety 
(HAMA, Hamilton, 1959), and the Positive and Negative Syndrome Scale (PANSS, Kay et 
al., 1987). The patients were recruited from October 2001- March 2005 from the Referral 
Centre for the Stress-related Disorders of the University Hospital Dubrava in Zagreb, Croatia. 
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The assessments and ratings were conducted by psychiatrists with extensive experience in 
stress-related disorders. Psychiatrists administered the SCID, CAPS, HDRS, HAMA, PANSS, 
as well as an additional psychiatric interview, which is routinely performed in every day 
clinical pratice at the department. The PANSS was used to detect pychotic features in PTSD 
patients (Kozaric-Kovacic and Pivac, 2006). Suicidal behavior was assessed by psychiatrists 
using item 3 from the HDRS 17-item scale (Hamilton, 1960): score 0, which indicates 
absence of any suicidal thoughts or ideation, score 1 (a person feels life is not worth living), 
score 2 (a person wishes he/she was dead or has any thoughts of possible death to 
him/herself), score 3 (a person has suicide ideas or gestures), and score 4 (a person attempted 
suicide). According to the item 3 of the HDRS, patients were categorized into two groups 
(Roggenbach et al., 2007): non-suicidal subjects (with 0 scores) and suicidal subjects (with 
scores ≥ 1). Among the PTSD patients, 73 male veterans were suicidal, while 47 male 
veterans were non-suicidal.  
Inclusion criteria: medication-free male combat veterans between 18-65 years old. 
Exclusion criteria: a family history of psychosis or PTSD, a prior episode of any psychosis, a 
positive history of schizophrenia spectrum disorders, bipolar disorder, neurodegenerative 
disorders, history of cognitive dysfunction or mental retardation, alcohol dependence, past or 
current alcohol or other substance abuse within 3 months, serious concomitant medical 
condition, clinically significant abnormalities in electrocardiogram or laboratory findings, 
including positive urine screen for illicit drugs and alcohol.  
Two control groups were established for this study. The first group consisted of non-
PTSD comparison psychiatric patients: 75 male patients with diagnoses other than PTSD 
(depression (N=35), psychosis (N=7), acute stress disorder (N=12), personality disorders 
(N=12), other diagnoses (N=9)). All patients, diagnosed using the SCID, were categorized 
into suicidal and non-suicidal patients, according to the item 3 of the HDRS: 45 suicidal and 
30 non-suicidal patients. These patients were drug-naïve or drug free for at least 2 weeks, and 
were not taking selective serotonin reuptake inhibitors (SSRI) during the previous 6 weeks. 
The second control group consisted of 147 medication-free healthy men with no personal or 
family history of psychopathology, no previous history of suicide attempt or family history of 
suicide, free of psychiatric disorders, and no current medical treatment.  
Study participants in the PTSD in the non-PTSD comparison group were recruited as 
consecutive in- and out-patients admitted during the indicated recruitment period, among 
patients who fulfilled the inclusion and exclusion criteria for either group. Healthy controls 
were recruited consecutively among people attending the ward as part of their regular medical 
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check-ups, who fulfilled the inclusion and exclusion criteria for the healthy control group. 
Groups were matched on mean age, education, and drug status. 
All participants completed the questionnaire regarding their medical history, drinking, 
and smoking habits. Patients and healthy controls were sampled in the same period of the year. 
Written informed consent was obtained from all participants, under procedures approved by 
the Ethics Committee of the University Hospital Dubrava, Zagreb, Croatia, and in accordance 
with the Declaration of Helsinki. 
 
2.2. Blood sample collection and testing  
Blood samples (8 ml) were drawn in a plastic syringe with 2 ml of acid citrate dextrose 
anticoagulant at 08.00 h. Platelet rich plasma (PRP) was obtained after centrifugation of whole 
blood at 950g for 30 sec at room temperature and platelets were sedimented by further 
centrifugation of PRP at 10,000g for 5 min in a refrigerated centrifuge. The platelet pellet was 
washed with saline and centrifuged again. The sedimented platelets were frozen and stored at -
20°C no longer than 7 days before being assayed for 5HT concentration.  
 
2.3. Platelet 5-HT measurement  
Platelet 5-HT concentration was determined by the spectrofluorimetric method, as previously 
described (Pivac et al., 2001). Briefly, platelets were destroyed by sonication (20 kHz, amplitude 
8 x 10-3 mm for 30 sec). Specimens of standard, blank (water) and platelet sonicates were 
analyzed in duplicate. All samples were deproteinized with 1 ml of 10% ZnSO4 and 0.5 ml of 1 
N NaOH. For the preparation of fluorophore, 0.2 ml of L-cysteine (0.1%) and 1.2 ml of 
orthophthalaldehyde (0.05%) were added to deproteinized samples. The measurement of the 5-
HT fluorescence was performed on a Varian Spectrophotofluorimeter Cary Eclipse, on an 
exciting wavelength of 345 nm and emitted wavelength of 485 nm. Platelet protein 
concentrations were measured by the method of Lowry et al. (1951).  
 
2.4. Statistical analysis 
The statistical analysis of the data was conducted with Statistica, release 6, Statsoft (Tulsa, 
Oklahoma, USA), and with Sigmastat 2.0 (Jandell Scientific Corp. San Raphael, California, 
USA). Results are shown as means ± standard deviations (SD) with 95% confidence intervals 
(CI).  The statistical evaluation of the results was performed using one-way analysis of variance 
(ANOVA) followed by the Tukey’s multiple comparison test. The correlation between 
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parameters was determined by a Pearson’s coefficient of correlation. All results were 
interpreted at 5% significance level (α=0.050).  
 
3. Results 
3.1. Characteristics of the subjects 
Data on the age and clinical scales scores in the veterans with PTSD and in non-PTSD 
patients are summarized in Table 1. There were no significant (F=2.556; df=3,191; p=0.057, 
ANOVA) differences in age between patients. Total CAPS scores, determined in PTSD 
patients, were similar (F=1.353; df=1,118; p=0.248) between suicidal and non-suicidal PTSD 
patients.  
 
All patients were evaluated with HDRS, and total HDRS scores differed significantly between 
the patient groups (F=31.569; df=3,191; p<0.001). Non-suicidal non-PTSD patients had 
significantly lower total HDRS scores than all other groups: suicidal non-PTSD patients 
(p<0.002), non-suicidal PTSD patients (p<0.001), and suicidal PTSD patients (p<0.001). 
Suicidal and non-suicidal PTSD patients had similar (p= 0.261) total HDRS scores, Table 1.   
 
Regarding suicide scores on HDRS item 3, PTSD patients had significantly higher suicide 
scores than non-PTSD patients (F=9.246; df=1,116; p<0.003).  
 
The total HAMA scores differed significantly between patients (F= 12.474; df=3,191; 
p<0.001), since suicidal PTSD patients had significantly higher (p<0.001) HAMA scores than 
non-suicidal PTSD patients, and suicidal non-PTSD patients had significantly higher 
(p<0.002) HAMA scores than non-suicidal non-PTSD patients.  
 
The total PANSS scores also differed significantly between patients (F=14.161; df=3,191; 
p<0.001), with suicidal PTSD (p<0.036) and non-PTSD (p<0.001) patients having 
significantly higher total PANSS scores than the corresponding non-suicidal patients. Non-
suicidal PTSD patients had significantly (p<0.005) higher total PANSS scores than non-
suicidal non-PTSD patients, Table 1. 
 
Among PTSD patients, 73 (61%) were suicidal, of those 32 (44%) felt that life is not worth 
living; 18 (25%) wished that they were dead or had thoughts of possible death; 15 (20%) had 
suicide ideas or gestures; and 8 (11%) had previous suicide attempts.  
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Of the 45 (67%) suicidal comparison patients who had diagnoses other than PTSD (non-
PTSD patients), 33 (73%) felt that life is not worth living; 7 (16%) wished that they were 
dead or had thoughts of possible death; 5 (11%) had suicide ideas or gestures; and none had 
attempted suicide. 
 
3.2. Platelet 5-HT concentration between suicidal and non-suicidal PTSD patients, 
psychiatric non-PTSD controls, and healthy control subjects 
 
Platelet 5-HT concentration differed significantly between all groups (F=5.546; df=4,337; 
p<0.001, ANOVA), Fig. 1. Tukey's test revealed significantly lower platelet 5-HT 
concentration in suicidal compared to non-suicidal (p<0.029) PTSD patients or healthy 
controls (p<0.001). Significantly higher platelet 5-HT concentration was found in non-
suicidal compared to suicidal psychiatric comparison controls (p<0.020) or healthy controls 
(p<0.013). Platelet 5-HT concentration did not differ significantly between healthy control 
subjects and non-suicidal PTSD patients (p=0.712). Suicidal non-PTSD patients had 
marginally lower platelet 5-HT concentration than healthy control subjects (p=0.072). 
 
3.3. The lack of effect of smoking on platelet 5-HT in patients 
Platelet 5-HT concentration did not differ significantly between PTSD and non-PTSD patients 
(F=0.808; df=3,151; p=0.493, ANOVA), who were categorized according to the smoking 
status into smokers or nonsmokers (Fig. 2).  
 
3.4. Platelet 5-HT concentration and severity of suicidal behavior in suicidal patients  
There were no significant correlations between platelet 5-HT and HDRS scores for suicidal 
behavior (item 3 of the HDRS) in suicidal PTSD patients (r=0.085; p=0.508), or suicidal non-
PTSD patients (r=-0.148; p=0.354).  
 
4. Discussion 
4.1. Principal findings 
 
In this comparative study with male subjects, suicidal veterans with combat related PTSD, 
and comparative suicidal patients with diagnoses other that PTSD (depression, psychosis, 
acute stress disorder, personality disorders, and other diagnoses), had lower platelet 5-HT 
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concentration than non-suicidal patients, while suicidal PTSD patients had lower platelet 5-
HT concentration than  control subjects. These findings are consistent with significantly 
decreased platelet 5-HT concentration found in suicidal depressed patients (Mann et al., 1992; 
Muck-Seler et al., 1996; Pivac et al., 1997; Rogenbach et al., 2007), in patients with a history 
of violent suicide attempts (Alvarez et al., 1999), in suicidal patients with a first episode of 
psychosis (Marcinko et al., 2007), in suicidal patients with schizophrenia (Braunig et al. 
1989), or schizoaffective disorder (Rao et al. 1994). Athough the importance of platelet 5-HT 
as a biological marker of suicidal behavior has recently been disputed (Mueller-Oerlinghausen 
et al., 2004), the present results, obtained on a large sample of male PTSD patients and male 
comparison patients without PTSD, together with previous data, obtained on a large number 
of psychotic and non-psychotic male and female depressed patients (Muck-Seler et al., 1996; 
Pivac et al., 1997), and a smaller number of male patients in acute psychosis (Marcinko et al., 
2007), argue that reduced platelet 5-HT concentration might serve as a predictor of suicidal 
behavior. In line with our data, attempted or completed suicides were reported to be related to 
reduced levels of 5-HT and 5-HIAA in blood and cerebrospinal fluid (CSF), (Nordstrom et 
al., 1994). Furthermore, suicide attempts were associated with lower CSF 5-HIAA 
concentrations in depressed patients (Mann and Malone, 1997), with fewer prefrontal cortex 
5-HT transporter binding sites (Mann et al., 2003), and upregulation of serotonergic post-
synaptic 5-HT1A and 5-HT2A receptors in the brain (Arora and Meltzer, 1989). In addition, 
more 5-HT2A binding and more mRNA in the postmortem prefrontal cortex tissue of suicide 
victims was found (Pandey et al., 2002).   
 
In a review questioning the use of platelet markers as predictors of suicidal behavior 
(Mueller-Oerlinghausen et al., 2004), the authors stressed the importance of large sample 
sizes and matching the patients for age, gender, season, drug status, smoking habits and 
different comorbidities. In our previous studies (Muck-Seler et al., 1996; Pivac et al., 1997) 
we carefully matched patients for these confounding factors. Namely, gender differences were 
detected in platelet 5-HT concentration in previous studies (Oxenkrug, 1979; Muck-Seler et 
al., 1996; 1999; Pivac et al., 2001; Roggenbach et al., 2007), and thereafter in our previous 
studies measuring platelet 5-HT all our patients were divided according to the sex. The 
present study included only male subjects, and therefore gender matching was not necessary. 
Smoking does not affect platelet 5-HT concentration in healthy subjects (Pivac et al., 2004) or 
in patients (present study), hence the data from smokers and nonsmokers were collapsed. 
Alcohol abuse can lower platelet 5-HT concentration (Pivac et al., 2004), and therefore we 
 10 
excluded patients with alcohol dependence, past or current alcohol or other substance abuse 
within 3 months. Although seasonality does not have any significant impact on platelet 5-HT 
concentration (Jakovljevic et al., 1997; Pivac et al., 2003), patients and comparative subjects 
were sampled consecutively in the same recruitment period. Medication such as SSRI reduces 
platelet 5-HT concentration (Muck-Seler et al., 2002; Muck-Seler et al 2005; Pivac et al., 
2003), and to avoid this influence, the participants in this study were not prescribed SSRI in 
previous 6 weeks. Although platelet 5-HT does not appear to differ according to diurnal 
rhythm (unpublished data), all subjects were sampled at the same time of day (i.e. at 08.00 
a.m.). Our study  consisted of a large number of male subjects (120 war veterans, with current 
and chronic PTSD, and 75 patients with diagnoses other than PTSD, as psychiatric control 
subjects; categorized according to suicidal behavior) and 147  medication-free healthy control 
subjects. It has been reported that other comorbid psychiatric diagnoses such as depression, 
schizophrenia, or borderline personality disorder, might affect biological parameters 
associated with suicidal behavior (Mueller-Oerlinghausen et al., 2004). In contrast to this 
suggestion, in veterans with PTSD, comorbid depression did not significantly affect platelet 
5-HT concentration (Muck-Seler et al., 2003). Since our PTSD patients did not suffer from 
schizophrenia or borderline personality disorder, and only 2 patients had comorbid 
depression, we can exclude the possibility that these diagnoses significantly affected platelet 
5-HT concentration. In addition, in our study suicidal comparison non-PTSD patients, with 
diagnoses of depression, psychosis, acute stress disorder, and personality disorders, also had 
lower platelet 5-HT concentration than non-suicidal patients, indicating a reduced platelet 5-
HT concentration associated with suicidal behavior across different diagnoses. Therefore, 
although the usefulness of platelet 5-HT, MAO-B, 5-HT2A receptor binding and tryptophan 
availability as potential biological markers for suicidal behavior has been questioned 
(Mueller-Oerlinghausen et al., 2004; Lauterbach et al., 2006), the same author group has 
recently reported significantly lower platelet 5-HT concentration in acute suicidal vs. non-
suicidal depressed patients (Roggenbach et al., 2007). Hence, our data support the suggestion 
that low serotonergic function is related to suicidal ideation and other personality traits 
characteristic for suicidal behavior, possibly through the collapse of the normal restraint 
mechanisms, thus contributing to the development of suicidal behavior (Lauterbach et al., 
2006). The lack of a significant correlation between suicide HDRS scores and platelet 5-HT 
concentration in veterans with PTSD and comparison non-PTSD patients was to be expected, 
since the majority of patients scored very low on item 3 of HDRS, and only few patients (7%) 
had attempted suicide. 
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If platelet 5-HT concentration had differed significantly between non-suicidal patients with 
PTSD and healthy control group, the significance of the altered platelet 5-HT concentration in 
suicidal behavior would be difficult to explain, since altered platelet 5-HT concentration 
might be related to the presence of psychotic symptoms such as delusions (Pivac et al., 
2006a), severe appetite loss (Muck-Seler et al., 2003), or some other traits in PTSD patients. 
However, in the present and our previous studies (Muck-Seler et al., 2003; Pivac et al., 2002; 
Pivac et al., 2006a; Pivac et al., 2006b), as well as in work from other groups (Maguire et al., 
1998; Mellman and Kumar, 1994; Cicin-Sajn et al., 2000), platelet 5-HT concentration was 
similar between PTSD patients and corresponding control subjects. These data confirm our 
hypothesis that the reduced platelet 5-HT concentration in suicidal veterans with combat 
related PTSD is a trait marker, predictive of suicidal behavior in PTSD. Therefore, our data 
agree with the presumption that biological parameters are more likely associated with single 
aspects of experience and behavior, such as suicidal behavior, than with a nosological 
constructs or entities (Mueller-Oerlinghausen et al., 2004; van Praag, 2004).  
 
Serotonin regulates divergent behaviors (Stahl, 1998; Lucki 1998) including suicidal behavior 
(Roy and Linoilla, 1988; Mann et al., 1996, Mann, 2003), and serotonergic 5HT1A and 
5HT2A receptors mediate anxiety (Bonne et al., 2004), antisocial and aggressive behavior 
(Goveas et al., 2004; Popova, 2006), impulsivity and violence (Askenazy et al., 2000). 
Suicidal behavior is associated with a deficient 5-HT system (Mann et al., 1998), and altered 
5-HT functioning was found in the ventromedial and lateral prefrontal cortex, which might be 
associated with the predisposition to suicidal behavior due to the impaired restraint 
mechanisms (Oquendo et al., 2003; Lauterbach et al., 2006). Our findings of the lower platelet 
5-HT concentration in suicidal PTSD and comparative psychiatric patients suggest that 
platelet 5-HT concentration is related to particular trait markers (Askenazy et al., 2000; Peirson 
et al., 1999), and that platelet 5-HT may distinguish between PTSD subjects with and without 
suicidal behavior.  
 
A few limitations of the study should be mentioned: platelet 5-HT was assessed only in one 
time point, and suicidal behavior was determined using HDRS item 3 scores (Rogenbach et 
al., 2007). Accordingly, patients were divided into non-suicidal (0 scores) and suicidal 
patients (with 1-4 scores, i.e. with feelings that life is not worth living, with wishes of death or 
any thoughts of possible death; suicide ideas or gestures, or suicide attempts). We should 
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emphasize that the strength of our study was in a large number (195) of patients, including 
PTSD and comparison psychiatric patients, of which 128 patients (61%) were categorized as 
suicidal. Out of them, 55% felt life is not worth living, 21% wished he/she was dead or had 
any thoughts of possible death to him/herself, and only a few patients had suicide ideas or 
gestures (17%), or suicide attempts (7%), as can be seen from the average (1.32-1.84) suicide 
scores. Therefore, our results show more merit, since platelet 5-HT concentration was 
significantly lower in patients with less pronounced suicidal behavior.  
 
Suicidal behavior is a major complication of psychiatric disorders, and according to the 
WHO, it accounts for almost 2% of the deaths in the world (Bondy et al., 2006).  In Croatia, 
the suicide rate oscillated depending on the source of the data (Register of Suicide of the 
Ministry of Interior, and Croatian Bureau of Statistics) for the period between 1985-2000 (i.e. 
pre-war, war and post-war periods in Croatia) (Grubisic-Ilic et al., 2002; Kozaric-Kovacic et 
al., 2002a; Kozaric-Kovacic et al., 2002b). The average suicide rate in Croatia was 17.83 - 
19.57 per 100 000 people in pre-war period, 16.59-19.52 during war and 17.78-19.78 in the 
post-war period (Grubisic-Ilic et al., 2002; Kozaric-Kovacic et al., 2002a; Kozaric-Kovacic et 
al., 2002b). However, a higher frequency of suicide was found in younger men during war, 
presumably due to the fact that a lot of veterans suffered from PTSD, but did not receive 
proper treatment during combat (Kozaric-Kovacic et al., 2002a). Therefore, an important goal 
in the treatment strategies of PTSD is to elucidate the association between biological 
biomarkers and suicidal behavior in PTSD, to facilitate the identification of the subjects who 
are prone to develop suicidal behavior, and to detect suicidal patients, in order to prevent 
suicidal attempts and to provide proper treatment for individual patients with PTSD at any 
given stage of the illness.  
 
In conclusion, our results have shown that suicidal veterans with combat related PTSD and 
comparison psychiatric non-PTSD patients, had lower platelet 5-HT concentration than non-
suicidal patients, indicating a reduced platelet 5-HT concentration associated with suicidal 
behavior. Our data suggest that platelet 5-HT might be used as an easily obtainable peripheral 
marker that might detect suicidal behaviour in combat related PTSD (present study), 
depression (Muck-Seler et al., 1996; Pivac et al., 1997), acute psychosis (Marcinko et al., 
2007), i.e. that platelet 5-HT might differentiate between suicidal and non-suicidal behavior 
across different psychiatric diagnoses, after carefull matching the patients for age, gender, 
diagnoses, and drug status. 
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Table 1. Age and clinical scores in male patients  
 
Variables Suicidal 
PTSD 
(N =73 ) 
Non-suicidal 
PTSD  
(N = 47) 
Suicidal non-
PTSD  
(N =45) 
Non-suicidal  
non-PTSD 
(N =30 ) 
Age (years) 39.13 ± 7.83 40.91 ± 8.29 40.15 ±  9.56 35.33 ±  10.67 
 
CAPS total 82.13 ± 13.60 78.85 ± 12.11 0 0 
 
HDRS total 22.13 ± 4.45 19.73 ± 4.45 23.90 ± 3.92 12.91 ± 7.91*,** 
 
HDRS item 
3  
1.84 ± 0.97 0 1.32 ±  0.65*** 0 
HAMA total 25.10 ± 6.62 22.51 ± 5.86• 24.78 ± 7.67 16.21 ± 8.52•• 
PANSS total 87.75 ± 19.96 76.42 ± 19.18# 79.48 ±  17.92 60.49 ±  21.09## 
 
 
CAPS, Clinician Administered PTSD Scale; HDRS, Hamilton Depression Rating Scale; 
HDRS item 3, Hamilton Depression Rating Scale item for suicidal behavior; HAMA, 
Hamilton Rating Scale for Anxiety;  PANSS, Positive and Negative Syndrome Scale;  PTSD, 
posttraumatic stress disorder.  
HDRS total scores: * p<0.002 vs. suicidal non-PTSD patients, ** p<0.001 vs. non-suicidal 
PTSD patients; ** p<0.001 vs. suicidal PTSD patients; HDRS item 3 scores: ***p<0.003 vs. 
suicidal PTSD patients; HAMA total scores: • p<0.001 vs. suicidal PTSD patients; •• 
p<0.002 vs. suicidal non-PTSD patients; PANSS total scores: # p<0.036 vs. suicidal PTSD 
patients; ## p<0.001 vs. suicidal non-PTSD patients (Tukey’s test). 
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Legend to the Figures: 
 
Fig. 1: Platelet 5-HT concentration (mean ± SD) in suicidal and nonsuicidal male veterans 
with PTSD, male suicidal and nonsuicidal comparative patients without PTSD, and in male 
healthy controls. * p<0.029 vs. non-suicidal PTSD patients; ** p<0.001 vs. healthy control 
men; # p<0.020  vs. suicidal non-PTSD patients; ## p<0.013  vs. healthy control men, 
Tukey’s test; 95% confidence intervals (CI) for 5-HT values: healthy men (CI=1.22-1.31); 
suicidal veterans with PTSD (CI=0.93-1.12); non-suicidal war veterans with PTSD (CI=1.03-
1.39); suicidal non-PTSD patients (CI=0.96-1.23); non-suicidal non-PTSD patients: (CI=1.14-
1.48).  
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Fig. 2: Platelet 5-HT concentration (mean ± SD) in male veterans with PTSD and male 
patients without PTSD, subdivided into smokers and nonsmokers.  95% confidence intervals 
(CI) for 5-HT values: patients with PTSD – smokers (CI= 0.93-1.26); patients with PTSD – 
non-smokers (CI= 1.06-1.53); non-PTSD patients – smokers: (CI= 0.98-1.43); non-PTSD 
patients – non-smokers: (CI= 0.99-1.25).  
 
 
 
 
 
 
 
 
